Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001
NCT01661725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2012-08-09
Summary
The clinical trial was designed to evaluate the safety against Group ACYW135 Meningococcal Polysaccharide Vaccine of Hualan administered on subjects 2 years of age and older.
Conditions
Interventions
- BIOLOGICAL
-
Group ACYW135 Meningococcal Polysaccharide Vaccine
60 subjects were divided into three groups (20 subjects each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Sponsors & Collaborators
-
Hualan Biological Engineering, Inc.
lead INDUSTRY
Principal Investigators
-
Fubao Ma, Bachelor · Immunization Program Institute of Jiangsu Provincial Center for Disease Control and Prevention
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 2 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-04-30
- Primary Completion
- 2006-04-30
- Completion
- 2006-05-31
More Related Trials
-
A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine
NCT04689165 ·Status: UNKNOWN ·Phase: PHASE3
-
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a 4 to 6 Year-old Population
NCT06011200 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months
NCT05229536 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds
NCT06700148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months
NCT06314659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase IV Clinical Study of Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
NCT05935176 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old
NCT02867319 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
NCT02003313 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine
NCT04689191 ·Status: UNKNOWN ·Phase: PHASE3
-
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
NCT00126945 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine
NCT00994695 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
NCT02003495 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
NCT00850603 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months
NCT02878291 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
NCT06226714 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years
NCT00196950 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.
NCT04236960 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
NCT01482052 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.
NCT00454909 ·Status: COMPLETED ·Phase: PHASE2
-
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
NCT01732627 ·Status: COMPLETED ·Phase: PHASE2
-
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
NCT00262041 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
NCT01165242 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China
NCT07135986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old
NCT00196976 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
NCT01154088 ·Status: COMPLETED ·Phase: PHASE3